AbbVie, Anima Biotech to Collaborate on mRNA Biology Modulators
January 10 2023 - 8:50AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. on Tuesday said it plans to work with privately held
Anima Biotech to discover and develop mRNA biology modulators for
three targets across oncology and immunology.
AbbVie, a North Chicago, Ill., biopharmaceutical company, said
Anima would use its mRNA Lightning platform to discover novel
biology modulators against the targets, providing AbbVie exclusive
rights to license and further develop and commercialize the
programs.
AbbVie said it would make an upfront payment of $42 million to
Anima, which is also eligible for up to $540 million in option fees
and research-and-development milestone payments across the three
targets, along with further commercial milestone payments and
royalties on product sales.
AbbVie said modulating mRNA biology with small molecules is a
new approach that has the potential to address "undruggable"
targets, with implications across multiple therapy areas.
The company said it has an option to expand the collaboration
with Anima by up to three additional targets under the same terms
as the initial agreement.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 10, 2023 08:35 ET (13:35 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
